SYMPATH

Reach α-synuclein-dependent neurodegeneration: clinical development of therapeutic AFFITOPE vaccines for Parkinson’s disease and multisystem atrophy

Coordinatore	AFFIRIS AG    more  Organization address address: KARL FARKAS GASSE 22 city: WIEN postcode: 1030 contact info Titolo: Prof. Nome: Achim Cognome: Schneeberger Email: send email Telefono: +43 17981575300 Fax: +43 7981575311
Nazionalità Coordinatore	Austria [AT]
Totale costo	7˙699˙474 €
EC contributo	5˙999˙706 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-10-01   -   2017-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	AFFIRIS AG  Organization address address: KARL FARKAS GASSE 22 city: WIEN postcode: 1030 contact info Titolo: Prof. Nome: Achim Cognome: Schneeberger Email: send email Telefono: +43 17981575300 Fax: +43 7981575311	AT (WIEN)	coordinator	2˙962˙400.00
2	FORSCHUNGSZENTRUM JUELICH GMBH  Organization address address: Leo-Brandt-Strasse city: JUELICH postcode: 52425 contact info Titolo: Mrs. Nome: Anke Cognome: Krüger Email: send email Telefono: +49 2461 615344	DE (JUELICH)	participant	789˙322.00
3	BIOLUTION GMBH  Organization address address: Karl-Farkas-Gasse 22 city: WIEN postcode: 1030 contact info Titolo: Dr. Nome: Iris Cognome: Grünert Email: send email Telefono: +43 1 786959513 Fax: +43 1786959520	AT (WIEN)	participant	685˙011.00
4	MEDIZINISCHE UNIVERSITAET INNSBRUCK  Organization address address: Christoph-Probst Platz 1 city: INNSBRUCK postcode: 6020 contact info Titolo: Dr. Nome: Wolfram Cognome: Rieneck Email: send email Telefono: +43 512 9003 70072 Fax: +43 512 9003 73400	AT (INNSBRUCK)	participant	366˙012.00
5	PROSENEX AMBULATORIUM BETRIEBSGMBH  Organization address address: Schottenfeldgasse 45 city: Wien postcode: 1070 contact info Titolo: Dr. Nome: Dieter Cognome: Volc Email: send email Telefono: +43 1 522 1309	AT (Wien)	participant	366˙012.00
6	CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE  Organization address address: "Rue Viguerie, Hotel-Dieu Saint Jacques 2" city: TOULOUSE postcode: 31059 contact info Titolo: Dr. Nome: Corinne Cognome: Joffre Email: send email Telefono: 33561778286 Fax: 33561778411	FR (TOULOUSE)	participant	345˙936.00
7	CHU HOPITAUX DE BORDEAUX  Organization address address: RUE DUBERNAT 12 city: TALENCE postcode: 33404 contact info Titolo: Mr. Nome: Jean-Jacques Cognome: Jalibert Email: send email Telefono: 33557820852 Fax: 33556796040	FR (TALENCE)	participant	328˙764.00
8	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Mrs. Nome: Muriel Cognome: Bouas Email: send email Telefono: 33562748360	FR (PARIS)	participant	156˙249.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The goal of SYMPATH is to advance clinical development of therapeutic vaccines targeting α-synuclein (aSyn)-driven neurodegenerative diseases (ND). It addresses Parkinson’s disease (PD) and multiple system atrophy (MSA), two synucleopathies, for which no causal therapy exists. Ultimately, both lead to patient disability and death, which along with patient number (PD) and age of onset (MSA, PD) define their high medical need status. The proposed programme focuses on 2 vaccine candidates, PD01A and PD03A, delivered by the innovative AFFITOME® technology. Both are peptide-protein conjugate vaccines and first-in-class candidates. They were selected to elicit antibodies neutralizing aSyn but sparing compensatory β-synuclein. Pre-clinical evaluation confirmed their disease-modifying activity in various models. The unprecedented clinical approach, called TANDEM strategy, uses the synergy resulting from applying 2 vaccine candidates in 2 complementary indications linked through their pathology. TANDEM PD/MSA capitalizes on (i) excellent clinical research centres and their associated national/European networks, (ii) platform methods assessing aSyn species as candidate biomarkers and (iii) preliminary clinical experience with PD01A, the first aSyn targeting vaccine ever tested in humans. Its core is formed by 2 phase I studies testing PD01A in MSA and PD03A in PD/MSA. Importantly, trial design (duration, endpoints, vaccine dose and schedule) will ensure collection of initial biomarker data connecting clinical results of PD- and MSA trajectories. SYMPATH defines the logical next development step of both AFFITOPE® vaccine candidates for synucleopathies and generates information/material (biobank) rendering them more amenable to rational drug development. Successful completion of the programme promises reaching aSyn pathology with an active vaccine as a causal therapy for PD/MSA, thus advancing one or both candidates as prime targets for product development and investment.'

Introduzione (Teaser)

Parkinson's disease ranks amongst the most common neurodegenerative disorders. European researchers are working on the first therapeutic vaccines that could improve disease outcome.